NCT07232602
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07232602
Title KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Acronym MK-3475-04D/KEYMAKER-U04
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ISR | FRA | ESP

Facility Status City State Zip Country Details
UCSF Medical Center at Mission Bay ( Site 5044) RECRUITING San Francisco California 94158 United States Details
Cleveland Clinic Taussig Cancer ( Site 5036) RECRUITING Cleveland Ohio 44195 United States Details
Huntsman Cancer Institute ( Site 5041) RECRUITING Salt Lake City Utah 84112-5550 United States Details
CHU de Bordeaux Hop St ANDRE ( Site 5607) RECRUITING Bordeaux Gironde 33075 France Details
Rambam Health Care Campus ( Site 5501) RECRUITING Haifa 3109601 Israel Details
Rabin Medical Center ( Site 5504) RECRUITING Petah Tikva 4941492 Israel Details
Severance Hospital, Yonsei University Health System ( Site 5903) RECRUITING Seoul 03722 South Korea Details
Asan Medical Center ( Site 5901) RECRUITING Seoul 05505 South Korea Details
Samsung Medical Center ( Site 5902) RECRUITING Seoul 06351 South Korea Details
Hospital Universitari Vall de Hebron ( Site 5767) RECRUITING Barcelona 08035 Spain Details
Hospital Clinico San Carlos ( Site 5765) RECRUITING Madrid 28040 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field